Eosinophilic Esophagitis
Conditions
Keywords
Eosinophilic Esophagitis, EoE, dysphagia
Brief summary
To determine how the esophagus in active and inactive stages of eosinophilic esophagitis tranmit fluids.
Interventions
OTHERD-xylose
There will be four patient groups analyzed. Ten patients each, 10 with active eosinophilic esophagitis defined by consensus guidelines, 20 patients in histologic remission (10 by steroids and 10 by diet) and 10 control volunteers will be studied. Patients who have consented to the trial will be scheduled at the Clinical Research Unit (CRU) Patients will report to Charlton 7 the CRU, having their height, weight, blood pressure and temperature recorded. Subjects can choose to either have a saline lock IV placed or have their bloods drawn 3 separate times. They will receive 25 grams of D-xylose orally. The D-xylose will be mixed in 10 cc of water with 2 teaspoons of honey. D-xylose serum levels will be drawn at 5 and 10 and 60 minutes.
Sponsors
Mayo Clinic
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients between the ages of 18 and 80 with eosinophilic esophagitis diagnosed by a combination of compatible symptoms, endoscopic findings, histology, and lack of response to proton pump inhibitors or negative pH study * endoscopy with esophageal and duodenal biopsies within two weeks of performance of this study * Patients between the ages of 18 and 80 with eosinophilic esophagitis diagnosed by a combination of compatible symptoms, endoscopic findings, histology, and lack of response to proton pump inhibitors or negative pH study, and are now in histologic remission( \<15phf) by the use of steroids or the six food elimination diet. * Volunteers will be selected for not having any history of esophageal symptoms
Exclusion criteria
* Vulnerable populations, such as those with diminished mental acuity, will be excluded. * Patients taking Nsaids within 48 hours of the d-xylose testing * artificial sweeteners within 48 hours of the d-xylose testing * History of IBD * Currently smoking or history of smoking * History of Celiac disease * Bacterial overgrowth, * motility disorders * other diffuse small bowel diseases.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reliability of the d-xylose testing defined by the serum levels | 1 year | D-xylose serum levels will be drawn at 5 and 10 and 60 minutes. D-xylose levels will be compared between the patients with active EOE and healthy controls using the Wilcoxon rank sum test. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| D-xylose testing compared to endoscopy/biopsy findings. | 1 year | Histologic parameters will include grading of spongiosis as an indicator of dilated intercellular spaces which will be correlated to serum levels of D-xylose. |
Countries
United States
Outcome results
None listed